Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Alumis Inc. is a clinical-stage biopharmaceutical company developing oral therapies for autoimmune and inflammatory diseases, with lead asset ESK-001 (a TYK2 inhibitor) in Phase 3 trials for systemic lupus erythematosus and plaque psoriasis. The company's exceptional 425% one-year return reflects positive clinical trial readouts and partnership momentum in a competitive immunology landscape dominated by Bristol Myers Squibb's Sotyktu and Sanofi's Dupixent. With $2.8B market cap, zero revenue, and 6.01x current ratio, Alumis represents a well-capitalized clinical-stage bet on next-generation oral immunology therapeutics.
Alumis operates a typical clinical-stage biotech model: raise capital through equity offerings, invest in R&D to advance pipeline candidates through FDA trials, then monetize through either direct commercialization (requiring sales infrastructure build-out) or partnering/licensing deals with larger pharmaceutical companies. The TYK2 inhibitor mechanism offers differentiation from JAK inhibitors (which face black box warnings) and potential best-in-class efficacy/safety profile. Pricing power will depend on demonstrating superiority versus established therapies in head-to-head trials and real-world evidence. The company's 6.01x current ratio suggests 18-24 months of cash runway at current burn rate, providing cushion to reach key Phase 3 milestones without immediate dilution risk.
ESK-001 Phase 3 trial data readouts in systemic lupus erythematosus (SLE) - primary endpoint achievement versus placebo on SLEDAI-2K score reductions
ESK-001 Phase 3 psoriasis trial results - PASI 75/90/100 response rates versus active comparator and safety profile differentiation from JAK inhibitors
FDA regulatory milestone achievements - IND clearances for new indications, breakthrough therapy designations, or priority review grants
Strategic partnership announcements with major pharmaceutical companies for co-development or commercialization rights
Equity financing events - dilutive secondary offerings to fund operations or non-dilutive debt facilities based on clinical progress
Competitive landscape developments - rival TYK2 or immunology programs showing superior efficacy or encountering safety issues
Binary clinical trial risk - Phase 3 failures in SLE or psoriasis would likely result in 70-85% market cap destruction given single-asset concentration. Historical Phase 3 success rates in autoimmune diseases approximate 50-60%.
Regulatory pathway uncertainty - FDA may require additional safety studies given JAK inhibitor class warnings, potentially delaying approval 12-24 months and increasing development costs $150-300M.
Reimbursement pressure - payers increasingly demanding real-world evidence and cost-effectiveness data before formulary inclusion, with autoimmune drugs facing step-edit requirements behind cheaper generics.
Patent cliff exposure - composition of matter patents typically expire 10-12 years post-approval, limiting commercial exclusivity window and requiring lifecycle management strategies.
Bristol Myers Squibb's Sotyktu (deucravacitinib) already approved for psoriasis with strong efficacy data, creating high bar for ESK-001 differentiation and potential market share challenges.
Sanofi/Regeneron's Dupixent dominance in inflammatory diseases with $11B+ annual sales and expanding label creates entrenched prescriber habits difficult to disrupt.
Next-generation oral immunology programs from Eli Lilly, AbbVie, and Pfizer targeting similar mechanisms could commoditize TYK2 inhibitor class before Alumis reaches market.
Biosimilar erosion of injectable biologic market may not translate to oral small molecule opportunity if payers maintain restrictive prior authorization requirements.
Cash runway constraints - $300M annual burn rate implies need for capital raise within 12-18 months unless partnership generates upfront payment. Dilutive financing at depressed valuations could occur if trial data disappoints.
Negative ROE of -75.5% and ROA of -56.1% reflect typical pre-revenue profile but underscore lack of asset productivity until commercialization. Extended development timelines amplify cumulative dilution to existing shareholders.
low - Clinical-stage biotechs are largely insulated from GDP fluctuations as trial timelines and regulatory processes follow scientific rather than economic cycles. However, severe recessions can impact: (1) ability to raise capital as risk appetite contracts, (2) patient enrollment if economic stress affects trial participation, and (3) post-approval commercial uptake if payers tighten formulary access. The company's current 6.01x liquidity ratio provides buffer against near-term funding market volatility.
Rising interest rates create significant headwinds through multiple channels: (1) Valuation compression - clinical-stage biotechs are valued on discounted cash flows 5-10 years out, making them highly duration-sensitive (similar to long-dated bonds). A 100bp rate increase can compress biotech valuations 15-25%. (2) Financing costs - while Alumis has minimal debt (0.10 D/E), future capital raises become more expensive as investors demand higher returns. (3) Opportunity cost - higher risk-free rates make speculative biotech investments less attractive versus safer alternatives. The 376% three-month return suggests momentum-driven positioning that could reverse sharply if the Fed maintains restrictive policy.
Minimal direct credit exposure as pre-revenue company with negligible debt. However, credit market conditions indirectly affect access to venture debt facilities (typically 15-25% of cash as non-dilutive financing option) and convertible note issuances. Widening high-yield spreads signal risk-off sentiment that typically correlates with biotech sector underperformance and reduced IPO/follow-on offering activity.
growth/momentum - The 425% one-year return and 376% three-month surge indicate speculative momentum positioning by hedge funds and retail traders betting on positive Phase 3 catalysts. Typical investor base includes: (1) Specialized healthcare hedge funds with clinical trial expertise, (2) Venture capital crossover funds bridging private/public markets, (3) Retail momentum traders chasing biotech volatility, (4) Event-driven funds positioning ahead of binary data readouts. Minimal dividend/value investor presence given zero revenue and negative cash flow. Institutional ownership likely concentrated among funds with high risk tolerance and 3-5 year investment horizons.
high - Clinical-stage single-asset biotechs routinely exhibit 40-60% annualized volatility and beta exceeding 2.0x versus broader market. The stock experiences 10-20% intraday swings around clinical trial updates, FDA communications, and sector rotation. Options implied volatility typically ranges 80-120%, reflecting binary event risk. Three-month 376% return demonstrates extreme momentum characteristics prone to sharp reversals. Investors should expect continued high volatility until Phase 3 data de-risks commercial probability.
